Cost of post-deployment screening for mental illness in the UK military: findings from a cluster randomised controlled trial.


Journal

Journal of mental health (Abingdon, England)
ISSN: 1360-0567
Titre abrégé: J Ment Health
Pays: England
ID NLM: 9212352

Informations de publication

Date de publication:
Dec 2022
Historique:
pubmed: 25 3 2019
medline: 24 1 2023
entrez: 24 3 2019
Statut: ppublish

Résumé

Little is known about the economic impact of military mental health screening. To investigate (a) whether post-deployment screening of military personnel affects use and cost of services and (b) the impact of psychiatric morbidity on costs. Participants were recruited from UK Royal Marine and Army platoons and randomised to an intervention group (which received tailored advice predicated upon mental health status) or a control group (which received general advice following assessment of mental health status). The intervention costs were calculated while service use and associated costs were assessed at 12-month follow-up. Data were available for 6323 participants. Mean screening cost was £34. Service costs were slightly higher in the control group compared to the intervention group (£1197 vs. £1147) which was not statistically significant (bootstrapped 95%CI, -£363 to £434. In both groups, screening and control, costs were significantly higher for those who screened positive for mental health problems. Costs were not affected by screening. In countries that have already implemented post-deployment screening, the political cost of disinvestment needs careful consideration. Those who develop psychiatric morbidity have substantially higher care costs than those who do not.

Sections du résumé

BACKGROUND UNASSIGNED
Little is known about the economic impact of military mental health screening.
AIMS UNASSIGNED
To investigate (a) whether post-deployment screening of military personnel affects use and cost of services and (b) the impact of psychiatric morbidity on costs.
METHODS UNASSIGNED
Participants were recruited from UK Royal Marine and Army platoons and randomised to an intervention group (which received tailored advice predicated upon mental health status) or a control group (which received general advice following assessment of mental health status). The intervention costs were calculated while service use and associated costs were assessed at 12-month follow-up.
RESULTS UNASSIGNED
Data were available for 6323 participants. Mean screening cost was £34. Service costs were slightly higher in the control group compared to the intervention group (£1197 vs. £1147) which was not statistically significant (bootstrapped 95%CI, -£363 to £434. In both groups, screening and control, costs were significantly higher for those who screened positive for mental health problems.
CONCLUSIONS UNASSIGNED
Costs were not affected by screening. In countries that have already implemented post-deployment screening, the political cost of disinvestment needs careful consideration. Those who develop psychiatric morbidity have substantially higher care costs than those who do not.

Identifiants

pubmed: 30902023
doi: 10.1080/09638237.2019.1581332
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

801-808

Auteurs

Beatrice Osumili (B)

King's Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Paul McCrone (P)

King's Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Howard Burdett (H)

Academic Department of Military Mental Health, King's College London, London, UK.

Norman Jones (N)

Academic Department of Military Mental Health, King's College London, London, UK.

Nicola T Fear (NT)

Academic Department of Military Mental Health, King's College London, London, UK.

Simon Wessely (S)

Academic Department of Military Mental Health, King's College London, London, UK.

Roberto J Rona (RJ)

Academic Department of Military Mental Health, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH